Mast Therapeutics, Inc. (NYSEMKT:MSTX) belonging to the Medical sector which declined -1.82% and closed its last trading session at $0.11.
The company reported its last EPS on 6/30/2016 and is expected to report its next EPS on 11/10/2016. Currently, the stock has a 1 Year Price Target of $3.5.
The consensus recommendation, according to Zacks Investment research, is 2.33. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell. The Stock had a 1 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 1 and 1 respectively.
Mast Therapeutics, Inc. on 6/30/2016 reported its EPS as $-0.05 with the analysts projecting the EPS of the stock as $-0.06. The company beat the analyst EPS Estimate with the difference of $0.01. This shows a surprise factor of 16.7%.
Many analysts have provided their estimated foresights on Mast Therapeutics, Inc. Earnings, with 5 analysts believing the company would generate an Average Estimate of $-0.05. Whereas they predicted High and Low Earnings Estimate as $-0.04 and $-0.05 respectively. While in the same Quarter Previous year, the Actual EPS was $-0.06.
The Company got Downgrade by Maxim Group on 21-Sep-16 from Buy to Hold.
Insider Trades for Mast Therapeutics, Inc. show that the latest trade was made on 26 Mar 2015 where Roberts Brandi L, the Chief Financial Officer completed a transaction type “Buy” in which 18000 shares were traded at a price of $0.5.
3 analysts projected Price Targets for Mast Therapeutics, Inc. The analysts believe that the company stock price could grow as high as $5. The Low Price target projection by analysts is $2.5 and the Mean Price Target is $3.5.
Mast Therapeutics, Inc. (NYSEMKT:MSTX) has the market capitalization of $21.01 Million. The company rocked its 52-Week High of $0.71 on Sep 6, 2016 and touched its 52-Week Low of $0.09 on Sep 30, 2016. The stock has Return on Assets (ROA) of -77.9 percent. Return on Equity (ROE) stands at -177.7% and Return on Investment (ROI) of 0 percent.
The stock is currently showing YTD performance of -74.29 Percent. The company has Beta Value of 0.66 and ATR value of 0.07. The Weekly and Monthly Volatility stands at 16.26% and 19.45%.
Mast Therapeutics Inc. is a biopharmaceutical research and development company focused on introducing new technologies for anticancer and antiviral treatments. The company’s lead product candidate is MST-188 for treating serious or life-threatening diseases. Mast Therapeutics, Inc., formerly known as ADVENTRX Pharmaceuticals, Inc., is based in San Diego, California.